Company Description
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States.
The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device.
In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature.
Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy.
It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors.
The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023.
Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
| Country | MD |
| Founded | 2015 |
| IPO Date | Oct 8, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 54 |
Contact Details
Address: 12510 Prosperity Drive, Suite 370 Silver Spring, Maryland 20904 United States | |
| Phone | 240-247-1143 |
Stock Details
| Ticker Symbol | ELUT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001708527 |
| Employer ID | 47-4790334 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kevin L. Rakin M.B.A, M.S. | Executive Chairman |
| Dr. C. Randal Mills Ph.D. | Co-Founder, President and Chief Executive Officer and Director |
| Matthew B. Ferguson | Chief Financial Officer |
| Erica Elchin | Vice President of Global Operations |
| Dr. Michelle LeRoux Williams Ph.D. | Chief Scientific Officer |
| Courtney Guyer | Vice President of Marketing |
| Dr. Sonali Fonseca Ph.D. | Vice President and Head of Emerging Businesses |
| Jeffry D. Hamet | Senior Vice President of Finance, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | 424B3 | Prospectus |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 8-K | Current Report |